RxDoctor Payments Data

Stanley Schwartz, MD

Internal Medicine · Moreno Valley, CANPI 1922067081

Payments from drug & device makers

$3,058in general payments, 2019–2025

Across 152 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$701
  • AbbVie$545
  • Lilly USA, LLC$192
  • Bayer$175
  • GSK$135
  • Boehringer Ingelheim$118
  • plus $1K from 33 others

What the payments were for

  • Food & beverage$3,058100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,058 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$124,977
Medicare patients
384
Services billed
2,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$81,458
OzempicSemaglutide57$55,567
JanuviaSitagliptin Phosphate40$44,826
Invega SustennaPaliperidone Palmitate12$42,975
RybelsusSemaglutide18$24,951
VraylarCariprazine Hcl13$18,438
LinzessLinaclotide29$18,107
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen399$13,827
Ondansetron Hcl43$11,705
CreonLipase/Protease/Amylase16$11,502
XareltoRivaroxaban14$10,812
JardianceEmpagliflozin17$10,787
TradjentaLinagliptin22$10,627
FarxigaDapagliflozin Propanediol13$9,723
PentasaMesalamine11$8,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$81,458124 claims
Novo NordiskOzempic, Rybelsus$701$80,51875 claims
MerckJanuvia, Belsomra, Steglatro$97$56,88970 claims
Johnson & JohnsonInvega Sustenna, Xarelto$66$53,78826 claims
AbbVieVraylar, Linzess, Creon, Lumigan$545$53,64071 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$118$28,02053 claims
AstraZenecaFarxiga$42$9,72313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Moreno Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →